Pfizer's stock, after facing post-pandemic market blues, is showing glimmers of a comeback. The stock recently logged a 4.10% ...

Novartis AG offers growth potential with a balanced drug portfolio, manageable debt, and shares priced below fair value. Click for my updated look at NVS stock.

In the fast-paced world of biotech investing, small-cap stocks often get overlooked. However, some have the potential to ...

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.